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Summary
Identification of the FMR1 gene and the repeat-ampli-
fication mechanism causing fragile X syndrome led to
development of reliable DNA-based diagnosticmethods,
including Southern blot hybridization and PCR. Both
methods are performed on DNA isolated from periph-
eral blood cells and measure the repeat size in FMR1.
Using an immunocytochemical technique on blood
smears, we recently developed a novel test for identifi-
cation of patients with fragile X syndrome. Thismethod,
also called “antibody test,” uses monoclonal antibodies
against the FMR1 gene product (FMRP) and is based
on absence of FMRP in patients’ cells. Here we describe
a new diagnostic test to identify male patients with frag-
ile X syndrome, on the basis of lack of FMRP in their
hair roots. Expression of FMRP in hair roots was studied
by use of an FMRP-specific antibody test, and the per-
centage of FMRP-expressing hair roots in controls and
in male fragile X patients was determined. Control in-
dividuals showed clear expression of FMRP in nearly
every hair root, whereas male fragile X patients lacked
expression of FMRP in almost all their hair roots. Men-
tally retarded female patients with a full mutation
showed FMRP expression in only some of their hair
roots (!55%), and no overlap with normal female con-
trols was observed. The advantages of this test are (1)
plucking of hair follicles does no appreciable harm to
the mentally retarded patient, (2) hairs can be sent in a
simple envelope to a diagnostic center, and (3) the result
of the test is available within 5 h of plucking. In addition,
this test enabled us to identify two fragile X patients
who did not show the full mutation by analysis of DNA
isolated from blood cells.
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Introduction
Fragile X syndrome (MIM 309550), the most common
inherited cause of intellectual disability, was one of the
first of an increasing number of neurogenetic disorders
in which a dynamic mutation of a trinucleotide repeat
was identified (Kooij et al. 1998). Expansion of a CGG
repeat to a full mutation of 1200 repeats within the
FMR1 gene results in hypermethylation of the FMR1
promoter and subsequent transcriptional silencing of the
FMR1 gene (Oberle´ et al. 1991; Verkerk et al. 1991;
Sutcliffe et al. 1992). The absence of the FMR1 gene
product (FMRP) is responsible for the mental retarda-
tion observed in fragile X syndrome (Devys et al. 1993;
Verheij et al. 1993).
The fragile X syndrome affects 1 in 4,000 males and
1 in 6,000 females (Turner et al. 1996; De Vries et al.
1997). In males, the methylated full mutation is always
associated with mental retardation, whereas ∼65% of
females with a full mutation have only mild mental
impairment.
The identification of the molecular basis of the fragile
X syndrome led to the development of reliable DNA-
based diagnostic methods (Rousseau et al. 1991a; Oos-
tra et al. 1993). Southern blot hybridization (Rousseau
et al. 1991a) and PCR (Fu et al. 1991; Brown et al.
1993) are mainly performed on DNA isolated from leu-
kocytes obtained from peripheral blood. Both DNA tests
determine the length of the CGG repeat in persons car-
rying the FMR1 gene, who can be divided into three
categories: (1) normal individuals with 6–53 CGG re-
peats (normal allele), (2) normal transmitting males and
unaffected females with a repeat length of 43–200 (pre-
mutation), and (3) patients with a repeat length of 1200
CGG repeats (full mutation).
Normal alleles and premutation alleles are usually
transcribed and translated, whereas full mutation alleles
are not transcribed and lead to the absence of FMR1
protein (Devys et al. 1993; Verheij et al. 1993). We have
described an alternative diagnostic test to identify pa-
tients with fragile X syndrome on the basis of the absence
of FMRP in lymphocytes. This antibody test can identify
persons with fragile X by means of only 1 or 2 drops
of blood (Willemsen et al. 1995, 1997). Advantages of
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this antibody test, compared with the DNA test, include
the following: (1) it can be performed in a single day;
(2) it does not require radioactivity; and (3) it detects
all loss-of-function mutations, including the prevalent
CGG repeat amplification and other mutations. Nev-
ertheless, a minority of fragile X patients still escape
detection by DNA tests and antibody tests on blood
smears. Some males with fragile X show only a pre-
mutation FMR1 allele and not a full mutation on South-
ern blots.
This report (1) describes the first results of a novel,
noninvasive antibody test on hair roots that can identify
individuals with fragile X and (2) describes other ad-
vantages of this test in the identification of fragile X
patients. In addition, we present two cases in which pa-
tients with the premutation showed FMRP expression




The first patient is a 4.5-year-old boy with psycho-
motor delay. He was born after an uneventful pregnancy
and delivery, weighing 2,500 g. During his first year, he
cried more than normal babies usually do. His devel-
opment was slow, and he first walked unaided at age 24
mo. At age 4.5 years, he has delayed mastery of language
and the speech of a 1.5-year-old. He is a restless boy
with difficulties in concentrating and in adapting to new
situations—e.g., hospitalizations and outpatient clinic
visits. He shows no dysmorphic features except for a
slight skull asymmetry. The parents have followed sec-
ondary education; the mother is working as a nurse and
the father is a skilled technical laborer.
The second patient is an 11-year-old boy with an IQ
of 77 (WISC-R). Clinical features include hyperexten-
sible metacarpophalangeal joints and otitis media. Be-
havioral features include language and concentration
problems and shyness. He has a 13-year-old brotherwho
is normal. The parents have followed secondary educa-
tion.
DNA Analysis
Genomic DNA was isolated from blood by the salting
out procedure, as described by Miller et al. (1988), and
5 mg of the genomic DNA was digested to completion
with HindIII. The DNA was electrophoresed on a 0.7%
agarose gel, transferred to a nylon membrane (Hybond
N, Amersham), and hybridized to the pP2 probe, which
detects a fragment containing the (CGG)n and the pre-
ceding CpG island (Oostra et al. 1993). After overnight
hybridization at 65C, the filters were washed to 0.3#
SSC/0.1% SDS at 65C, and the signal was detected by
autoradiography. PCR analysis was performed accord-
ing to Fu et al. (1991).
Hair Root Analysis
Informed consent was given, and hair roots were ob-
tained from the two patients, the control group of 130
normal individuals (males and females), 34 fragile X
patients with mental retardation (22 males and 12 fe-
males), and 15 mentally retarded individuals without the
fragile X syndrome. The fragile X syndrome had been
excluded in this last group by DNA analysis. A pair of
tweezers was used to pluck ∼10–20 hair roots from dif-
ferent areas behind the ear on the scalp. Hair with visible
bulbs and sheaths were selected and trimmed to just
above the sheath. After fixation within 4 h in 3% par-
aformaldehyde at room temperature (RT) for 10 min,
cells were permeabilized by treatment with 100%meth-
anol at RT for 20 min. After being washed with phos-
phate-buffered saline, containing 0.15% glycine and
0.5% bovine serum albumin, hair roots were incubated
as whole mount with mouse monoclonal antibodies
against FMRP at RT for 90 min. Visualization of an-
tibody-antigen complexes was achieved by means of an
indirect alkaline phosphatase technique, with goat an-
timouse immunoglobulins conjugated with biotin (Bio-
genex) and streptavidin-biotinylated alkaline phospha-
tase complex (Biogenex) used as second and third steps,
respectively. The new fuchsin substrate–chromogen sys-
tem (DAKO), which utilizes alkaline phosphatase activ-
ity, was used for 10–15 min during the final staining
step. Levamisole was added in the substrate solution,
according to the guidelines of the manufacturer, to block
endogenous alkaline phosphatase activit. Immunolabe-
led hair roots were examined with a stereo zoom mi-
croscope at a final magnification of 70#. An investi-
gator who was unaware of the phenotype of the
individual randomly numbered and scored all the hair
roots for presence or absence of FMRP. The number of
FMRP-positive hair roots showing red color was ex-
pressed as a percentage of the total number of hair roots
examined. Different storage conditionswere investigated
during the course of the study. Normal hair roots were
either stored at RT for several days (maximum 10 d) or
directly frozen on dry ice and stored at80C until used.
In hair roots that are stored at RT, the level of FMRP
expression gradually decreases with time. Therefore, the
immunoprotocol was adapted for hair roots that were
stored at RT, by incubation of the mouse antibodies
against FMRP for 16 h at 4C instead of 90 min at RT.
For detailed technical information about the antibody
test, please visit our website (http://www.eur.nl/fgg/ch1/
fragx/).
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Results
The two boys with cognitive deficits were tested for
fragile X syndrome, and in both cases we identified the
presence of a premutation in DNA isolated from white
blood cells. The 4.5-year-old boy showed a repeat size
of 60 and the 11-year-old boy a repeat size of 190 CGGs.
No full mutation could be detected (data not shown).
As the presence of a premutation alone could not explain
the psychomotor delay in the children, we tried to ex-
clude the presence of a mosaic pattern with a full mu-
tation in other tissues, including the brain. In an effort
to test for the mutation in an accessible tissue whose
lineage during embryonal development is closer to brain
cells, we decided to set up a method to test the expression
of the FMR1 gene in hair roots.
The expression of FMRP in a hair root from a control
individual is illustrated in figure 1a. The highest ex-
pression is observed in the bulb, and the labeling grad-
ually decreases in the direction of the hair shaft. Al-
though the positive reaction—a red color caused by
precipitation—can already be seen macroscopically,
scoring was performed with a stereo zoom microscope.
The detection of FMRP in hair roots that were stored
frozen or at RT (for 10 d) was unchanged under these
storage conditions. Figure 2 shows the percentage of
FMRP-expressing hair roots from normal individuals,
mentally retarded individuals not having fragile X syn-
drome, and male and female patients with fragile X syn-
drome. Most hair roots from controls showed positive
staining (range, 77%–100%), and ∼40% of the controls
had 10%–20% of hair roots without clear FMRP ac-
tivity (fig. 2). Unlabeled hair roots in normal individuals
probably result from technical occurrences during the
procedure (fixation, permeabilization, and immunoincu-
bation).
Most hair roots from male fragile X patients were
devoid of FMRP (fig. 1b); only in 10 of 22 male patients
was a mosaic pattern seen with the presence of 30%
normally staining hair roots (fig. 2). This is in line with
the percentage of affected males showing a mosaic ge-
notype at the DNA level (Rousseau et al. 1991a; Nolin
et al. 1994; De Graaff et al. 1995).
Female subjects with a full mutation and some intel-
lectual impairment showed a variable expression (range,
0%–55%) of FMRP in hair roots (fig. 1c), with either
positive-labeled or completely negative-labeled hair
roots. No overlap existed in the percentage of FMRP-
expressing hair roots between control individuals and
the tested fragile X patients. The expression pattern of
FMRP in hair roots from affected individuals without
fragile X syndrome showed a percentage within the nor-
mal range in all 15 persons. With this newly developed
method, the two boys with cognitive deficits and a pre-
mutation but no detectable full mutation in their blood
cells, along with their mothers, were tested for FMRP
expression in hair roots. We found FMRP expression in
83% and 90% of the hair roots of the respective moth-
ers, which is clearly in the normal range (fig. 2). The
normal brother in the second case showed an FMRP
expression of 100%. On the other hand, the 4.5-year-
old boy showed FMRP expression in only 27% of his
hair roots, and the 1-year-old boy showed an FMRP
expression of 11%, both of which are in the range of
fragile X patients with a mosaic pattern (fig 2).
Discussion
In the 1970s, human hair roots were frequently used
for biomedical research, especially for diagnosis of in-
born errors of metabolism. In particular, the detection
of female carriers of X-linked disorders, such as Lesch-
Nyhan syndrome, glucose-6-phosphate dehydrogenase
deficiency, and Fabry disease, benefited from biochem-
ical analysis of hair roots (Gartler et al. 1969, 1971;
Vermorken et al. 1978).
In the present study, FMRP expression in hair follicles
was examined in an effort to develop a noninvasive test
for detection of patients with fragile X syndrome. In
control individuals, both male and female, we were able
to detect FMRP expression in most hair roots, whereas
in male fragile X patients, we observed no expression
in the majority of hair roots. The observed mosaic pat-
tern in some male fragile X patients with expression of
FMRP in a minority of their roots is compatible with
the finding of a mosaic DNA pattern in peripheral leu-
kocytes from 40% of the affected males (Nolin et al.
1994). However, there is no overlap between control
individuals and affected fragile X males with a mosaic
pattern in the percentages of hair roots expressing
FMRP. In our study, the highest percentage found in the
group of fragile X males was 33%, whereas for normal
individuals the lowest percentage was 77%. Therefore,
this novel test on hair roots enables reliable identification
of male fragile X patients.
For reliability, the number of hair roots analyzed was
10 for males and 20 for females. All individuals in our
study had a positive opinion about the invasive character
of hair plucking—subjects experienced hair plucking as
less invasive than drawing blood. The advantages of the
use of hair roots for diagnostic purposes rather than
blood are obvious. First, hair roots can be plucked sim-
ply and without appreciable harm to the patient—
considerable advantages in sampling mentally retarded
patients. Second, afterbleeding and infections, which are
possible complications of blood sampling, are avoided.
Third, qualified medical personnel are not needed to
perform hair plucking. And last, large quantities of hair
follicles from many individuals can be sent by routine
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Figure 1 Microscopic localization, by means of the indirect alkaline phosphatase immunolabeling technique, of FMRP in hair roots from
a control individual (a), a male patient with fragile X syndrome (b), and a mentally retarded female patient with a full mutation (c). Expression
of FMRP is seen as a red precipitate. In control individuals, the red color of the precipitate is clearly visible in the root, and the high expression
seen in the bulb gradually decreases upward to the shaft (a). Hair roots from affected males are devoid of FMRP labeling (b). In affected
females with a full mutation, hair roots are either positive or totally negatively labeled (c).
postal service to a diagnostic laboratory for analysis
within 1 d.
Routine diagnosis of fragile X syndrome is mainly
performed by use of DNA isolated from white blood
cells. Recently, we described an antibody test to identify
fragile X patients by means of an immunocytochemical
technique using blood smears (Willemsen et al. 1995).
This test, which uses monoclonal antibodies against
FMRP, is based on the absence of FMRP in peripheral
lymphocytes. We have validated this method and have
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Figure 2 Distribution of the percentage of FMRP-expressing
hair roots from affected males ( ) (blackened squares), affectedn  22
females with a full mutation ( ) (blackened circles), and affectedn  12
individuals without fragile X syndrome ( ) (unblackened dia-n  15
monds). Arrowheads indicate the control range (77%–100%; n 
). On the right, two affectedmales (blackened squares), with FMRP130
expression in only a minority of hair roots, and their mothers (un-
blackened circles), with FMRP expression in the range of normal
individuals.
shown a high reliability and specificity for detectingmale
patients (Willemsen et al. 1997). Unfortunately, this
method uses blood cells, too, as a source for protein
analysis, with disadvantages similar to those of DNA
analysis, including blood sampling, possible complica-
tions, and origin of blood cells that come from a me-
sodermal lineage. Both antibody tests on blood smears
and hair root analysis have the advantage of having the
test results within 1 d.
The power of the technique was further illustrated by
the identification of two fragile X patients who could
not be diagnosed by DNA analysis. Southern blot anal-
ysis had shown a premutation without a detectable full
mutation; premutation alleles are unmethylated and re-
sult in normal FMRP expression. Testing hair roots af-
fords the opportunity of testing a different tissue. Lym-
phocytes originate from connective tissue, which arises
from mesoderm. In contrast, both neurons and skin de-
velop from the ectoderm. It has also been suggested that
there might be a selection against cells with a full mu-
tation in dividing lymphocytes or that there is a bias
toward inactivation of the X chromosome in women
during aging (Rousseau et al. 1991b). This may explain
why there might be a better correlation between (the
lack of) FMRP expression in hair roots and mental
retardation.
In summary, this novel test on hair roots is nonin-
vasive, rapid, and inexpensive. In addition, the test al-
lows identification of male and female patients and, in
exceptional cases, patients who could not be diagnosed
by routine DNA analysis. For these reasons, this test
might be ideal to screen populations of intellectually
disabled individuals for the fragile X syndrome. In only
a limited number of cases is the cause of mental handicap
known. Furthermore, the fragile X syndrome is consid-
ered to be an underdiagnosed disorder, and the number
of fragile X patients in The Netherlands who are not
yet diagnosed is estimated to be 65% (De Vries et al.
1997). It might be expected that this percentage is similar
in other countries with comparable widespread access
to genetic services and even higher in countries without
such access. Therefore, the development of a noninvasive
test might be valuable. Identification of patients with the
fragile X syndrome is important because (1) it allows
early intervention with behavioral management strate-
gies and education and (2) it allows genetic counseling
for family members at risk. Recently, several approaches
to screening for the fragile X syndrome have been in-
troduced. These can be divided into two strategies—case
finding, with cascade screening of family members at
risk, and population screening (Wildhagen et al. 1998).
This antibody test on hair roots has great potential for
case finding in screening programs for detection of frag-
ile X patients in institutions for the mentally handi-
capped or in schools for children with learning disabil-
ities, followed by cascade screening of family members
at risk. The experience obtained with such programs can
later be applied to large population-screening programs.
In affected females, the situation is more complex be-
cause of the presence of two X chromosomes and the
random inactivation of one of them. Thus, either the
normal or the mutated X chromosome is active. Since
human hair roots are of clonal origin (Gartler et al.
1969; Dancis et al. 1981), females with a full mutation
will have hair roots that are either completely normal
(the mutant FMR1 allele has been inactivated by the
lyonization process) or completely deficient (the wild-
type FMR1 allele has been inactivated by the lyonization
process), without FMRP expression. In this study, we
included only females with a full mutation who were
intellectually disabled in varying degrees. Our results
show no overlap in FMRP expression between control
individuals and this group of affected females, suggesting
a discriminating power of the test for affected women
versus controls. Further studies should be performed to
show whether this method will enable discrimination
between affected and unaffected females with a full mu-
tation. With DNA analysis or an antibody test on blood
smears, we have not been able to discriminate between
affected and normal females with a full mutation (De
Vries et al. 1996; Willemsen et al. 1997). Apparently,
the X-inactivation pattern in blood is not similar to the
X-inactivation pattern in neurons from the brain. Hair
roots might be of value for predicting the mental ca-
pacities of females with a full mutation, because they
originate, like brain tissue, during embryonic develop-
ment from the ectoderm. It is likely that the X-inacti-
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vation pattern within the ectoderm during early devel-
opment will give rise to similar X-inactivation patterns
in the brain and in hair roots. Studies to evaluate this
hypothesis are in progress.
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